Year 2023 / Volume 115 / Number 4
Original
Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis

168-174

DOI: 10.17235/reed.2022.8863/2022

Tiaotiao Miao, Yao Zhang, Lin Bai, Xiangqian Yang, Xinli Wen,

Abstract
Background: Vonoprazan is a potassium competitive acid blocker (P-CAB) approved in Japan in 2014 to treat endoscopic submucosal dissection (ESD)-induced ulcers and bleeding or perforation. Therefore, this meta-analysis aimed to determine whether Vonoprazan is more effective than Lansoprazole in the treatment of ESD-induced ulcers which include ulcer healing and shrinking rate, among others. Methods: Randomized controlled trials (RCT) and retrospective studies were collected from the PubMed (Medline), Embase, Web of science and Cochrane Library databases. Meanwhile, studies were selected according to predetermined qualification criteria and data were extracted by two researchers. The quality of the methods for published papers was evaluated using the modified Jadad scale. Results: Five studies were included in this meta-analysis, the ulcer healing rate effect was not significantly higher in the intervention groups than in the control groups at 4 weeks, [OR:1.07 (0.51, 2.22), 95% CI, I2=2%, Z=0.18, P=0.86]. There was no significant difference in the ulcer shrinkage rate at 4 weeks [MD:0.20 (-1.51, 1.92), 95% CI, I2=0%, P=0.82] and 8 weeks [MD: -0.09 (-0.30, 0.12), 95% CI, I2=0%, P=0.39]. Conclusion: There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD.
Share Button
New comment
Comments

17/04/2023 23:55:36
RECOVERY OF LOST FUNDS FROM SCAMMER.

Tracking Down Lost Bitcoins and Other Cryptos: Fast without wasting time Contact: Telegram: https://t.me/WizardWebRecovery / Email: wizardwebrecovery@gmail.com, Do you need support of recovery of your lost or stolen bitcoin, trying to obtain cryptocurrency transferred to the wrong wallet address, or believe your wallet has been compromised, get in touch with Wizard Web Recovery Group Hackers . I lost over 412,040 $ after participating in a SINCODE binary scam. The money I fraudulently lost has been recovered thanks to the super work of Wizard Web Recovery Group Hackers . They Working with the new digital software that recovers funds without a twinkle of eyes beep Wizard Web Recovery Group Hackers is trustworthy you can always contact them via
Telegram: https://t.me/WizardWebRecovery
Email: wizardwebrecovery@gmail.com


References
[1]Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc. 2016;28(1):3-15.
[2]Tate DJ, Klein A, Sidhu M, et al. Endoscopic submucosal dissection for suspected early gastric cancer: absolute versus expanded criteria in a large Western cohort (with video). Gastrointest Endosc. 2019;90(3):467-479.e4.2
[3]Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol. 2006;41(10):929-942.
[4]Bhatt A, Abe S, Kumaravel A, et al. Indications and Techniques for Endoscopic Submucosal Dissection. Am J Gastroenterol. 2015;110(6):784-791.
[5]Nishizawa T, Yahagi N. Long-Term Outcomes of Using Endoscopic Submucosal Dissection to Treat Early Gastric Cancer. Gut Liver. 2018;12(2):119-124.
[6]Tanabe S, Ishido K, Higuchi K, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center. Gastric Cancer. 2014;17(1):130-136.
[7]Wang KK, Prasad G, Tian J. Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. Curr Opin Gastroenterol. 2010;26(5):453-458.
[8]Yang Z, Wu Q, Liu Z, et al. Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials. Digestion. 2011;84(4):315-320.
[9]Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439-443.
[10]Kondo M, Kawamoto M, Hasuoka A, et al. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2012;17(2):177-182.
[11]Graham DY, Dore MP. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology. 2018;154(3):462-466.
[12]Martinucci I, Blandizzi C, Bodini G, et al. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother. 2017;18(11):1145-1152.
[13]Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337(3):797-804.
[14]Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636-648.
[15]Ichida T, Ueyama S, Eto T, et al. Randomized Controlled Trial Comparing the Effects of Vonoprazan Plus Rebamipide and Esomeprazole Plus Rebamipide on Gastric Ulcer Healing Induced by Endoscopic Submucosal Dissection. Intern Med. 2019;58(2):159-166.
[16]Komori H, Ueyama H, Nagahara A, et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. J Int Med Res. 2019;47(4):1441-1452.
[17]Hamada K, Uedo N, Tonai Y, et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. J Gastroenterol. 2019;54(2):122-130.
[18]Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial. Dig Endosc. 2017;29(5):576-583.
[19]Olivo SA, Macedo LG, Gadotti IC, et al. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88(2):156-175.
[20] Greenhalgh T. Assessing the methodological quality of published papers. BMJ. 1997;315(7103):305-308.
[21].Oremus M, Wolfson C, Perrault A, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord. 2001;12(3):232-236.
[22]Kawai D, Takenaka R, Ishiguro M, et al. Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. BMC Gastroenterol. 2021;21(1):236. Published 2021 May 22.
[23]Takahashi K, Sato Y, Kohisa J, et al. Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers. World J Gastrointest Endosc. 2016;8(19):716-722.
[24]Ban H, Inatomi O, Murata M, et al. Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study. J Clin Biochem Nutr. 2021;68(3):259-263.
[25]Hirai A, Takeuchi T, Takahashi Y, et al. Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers. Dig Dis Sci. 2018;63(4):974-981.
[26]Uchida E, Kato S, Tsuchiya I, et al. Percent reduction of the ulcer size at 4 weeks is a predictor of the complete healing of endoscopic submucosal dissection-induced gastric ulcers. Arab J Gastroenterol. 2020;21(3):183-188.
[27]Yoshizawa Y, Sugimoto M, Sato Y, et al. Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial. Dig Endosc. 2016;28(2):162-172.
[28]Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018;24(3):334-344.
[29]Marabotto E, Ziola S, Savarino V, et al. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. Clin Exp Gastroenterol. 2020;13:99-104. Published 2020 Apr 15.
[30]Inatomi N, Matsukawa J, Sakurai Y, et al. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12-22.
[31]Martinucci I, Blandizzi C, Bodini G, et al. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother. 2017;18(11):1145-1152.
[32]Repici A, Hassan C, De Paula Pessoa D, et al. Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review. Endoscopy. 2012;44(2):137-150.
[33]Ma MX, Bourke MJ. Complications of endoscopic polypectomy, endoscopic mucosal resection and endoscopic submucosal dissection in the colon. Best Pract Res Clin Gastroenterol. 2016;30(5):749-767.
Related articles

Letter

A large perforated gastric ulcer due to cocaine use

DOI: 10.17235/reed.2022.8676/2022

Letter

Gastric ulcer with liver penetration

DOI: 10.17235/reed.2022.8528/2021

Digestive Diseases Image

Bezoar: an uncommon cause of upper gastrointestinal bleeding

DOI: 10.17235/reed.2021.8311/2021

Citation tools
Miao T, Zhang Y, Bai L, Yang X, Wen X. Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. 8863/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 2342 visits.
This article has been downloaded 183 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 13/04/2022

Accepted: 08/07/2022

Online First: 28/07/2022

Published: 03/04/2023

Article revision time: 73 days

Article Online First time: 106 days

Article editing time: 355 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology